The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma. It affects thousands across the UK ...

VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...

Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has progressed after chemotherapy and immunotherapy.

Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Some experts are calling for universal lung cancer screening.

Every July, Sarcoma Awareness Month reminds us of a cancer that’s often sidelined in public discourse. However, sarcoma is not just one disease, it is a group of rare cancers with over 150 subtypes, ...

Sabari recommends regular activity, such as walking 30 minutes a day several times a week, to help maintain lung strength.

Immunotherapy in NSCLC faces challenges like high costs, limited access, and the need for optimized dosing and understanding of drug mechanisms. Precision medicine in breast cancer is evolving with ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment, Memorial ...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of pat ...